BioLineRx Ltd.
BLRX evidence brief
What we can confirm
- Market Cap:
- $10.6M
What it means
What to watch
Prepared research question
What matters most for BLRX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BLRX
BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases, with one FDA-approved product (APHEXDA/motixafortide) for stem-cell mobilization, now out-licensed to partners, and a pipeline centered on in-licensed assets and investigator-initiated trials.
Key risk: Limited cash runway
Market Cap
$10.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 4 clinical trials for BioLineRx Ltd..
BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases, with one FDA-approved product (APHEXDA/motixafortide) for stem-cell mobilization, now out-licensed to partners, and a pipeline centered on in-licensed assets and investigator-initiated trials.
- First approved product APHEXDA (motixafortide) was approved by the FDA in September 2023 for stem-cell mobilization in multiple myeloma [sec · filed 2026-03-23].
- Global rights to motixafortide (excluding solid tumors) were out-licensed to Ayrmid in November 2024, and Asian rights to Gloria in October 2023 [sec · filed 2026-03-23].
- Cash & equivalents were $3.2M as of 2025-12-31 [sec].
- Accumulated losses through December 31, 2025 were $401 million [sec · filed 2026-03-23].
- A Phase 2b trial in first-line PDAC (sponsored by Columbia University, supported by BioLineRx and Regeneron) is ongoing, with a pre-specified interim futility analysis planned for 2026 [sec · filed 2026-03-23].
What works
- The company has an FDA-approved product (APHEXDA) generating potential milestone and royalty income through out-licensing deals with Ayrmid and Gloria [sec · filed 2026-03-23].
- The investigator-initiated Phase 2b PDAC trial is conducted at relatively minimal cost to BioLineRx, with support from Regeneron [sec · filed 2026-03-23].
- BioLineRx has a disciplined in-licensing strategy, recently adding GLIX1 from Hemispherian AS, with back-ended, success-based consideration [sec · filed 2026-03-23].
- The company has reduced its cash burn rate by shutting down U.S. commercialization activities and refocusing on development in Israel [sec · filed 2026-03-23].
What to weigh
- BioLineRx has incurred accumulated losses of $401 million through December 31, 2025, and expects to continue incurring losses [sec · filed 2026-03-23].
- Cash & equivalents were only $3.2M as of 2025-12-31, which may limit operational runway without additional financing [sec].
- The company has no independent commercialization infrastructure for its approved product, relying entirely on partners [sec · filed 2026-03-23].
- The pipeline is heavily dependent on investigator-initiated trials and partner-funded studies, giving BioLineRx limited control over timelines [sec · filed 2026-03-23].
From the filings
Quoted directly from source documents.
FDA approval of APHEXDA for stem-cell mobilization
“on September 8, 2023, was approved by the FDA for use in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.”
SEC filings · March 23, 2026
Out-licensing of motixafortide rights to Ayrmid and Gloria
“in November 2024, we out-licensed the global rights (other than in Asia) to motixafortide for all indications, other than solid tumors, to Ayrmid.”
SEC filings · March 23, 2026
Accumulated losses of $401 million
“We have incurred accumulated losses in the amount of $401 million through December 31, 2025”
SEC filings · March 23, 2026
Phase 2b PDAC trial interim futility analysis planned for 2026
“a pre-specified interim futility analysis will be conducted when 40% of progression free survival events are observed, which is planned for 2026.”
SEC filings · March 23, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash & equivalents of $3.2M as of 2025-12-31 may be insufficient to sustain operations without new funding [sec].
- Dependence on partners — Revenue and development rely on out-license partners (Ayrmid, Gloria) and investigator-initiated trials, reducing direct control [sec · filed 2026-03-23].
- No near-term product revenue — With commercialization activities shut down, the company has no direct product sales and expects continued losses [sec · filed 2026-03-23].
- Pipeline execution risk — Key trial (Phase 2b PDAC) is investigator-initiated; enrollment and data timelines may shift [sec · filed 2026-03-23].
What to watch
- Interim futility analysis of the Phase 2b PDAC trial, planned for 2026 [sec · filed 2026-03-23].
- Progress of the GLIX1 collaboration with Hemispherian AS, including any clinical milestones [sec · filed 2026-03-23].
- Cash position and any new financing or partnership deals given the low cash balance [sec].
- Data from the Phase 1 SCD gene therapy study (St. Jude), with data planned in 2026 [sec · filed 2026-03-23].
Sources: SEC filings · Generated September 25, 2026 · How we verify sources →
Run BioLineRx Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BioLineRx Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 3.6%
- Days to cover
- 8.9
- Shares short
- 154,748
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BLRX short interestFrequently asked questions
What is the AI investment thesis for BioLineRx Ltd.?
BioLineRx Ltd. is a biopharmaceutical company focused on oncology and rare diseases, with one FDA-approved product (APHEXDA/motixafortide) for stem-cell mobilization, now out-licensed to partners, and a pipeline centered on in-licensed assets and investigator-initiated trials.
Who is the CEO of BioLineRx Ltd.?
Mr. Philip A. Serlin CPA, M.B.A. is the chief executive officer of BioLineRx Ltd. (BLRX).
Where is BioLineRx Ltd. headquartered?
BioLineRx Ltd. (BLRX) is headquartered in Hevel Modi'in, Israel.
What therapeutic areas does BioLineRx Ltd. focus on?
BioLineRx Ltd. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.